The UK now has 141 clinics licensed by the Human Fertilisation and Embryology Authority, its fertility regulator, across treatment, research and storage, six more than the year before. Of the 107 licensed specifically for fertility treatment, London is home to 36 of them, more than three times as many as the South East, the next largest region with 10. Northern Ireland has three and Wales has four. However the rest of England and Scotland’s clinics are distributed, London alone accounts for roughly a third of the country’s entire treatment-licensed fertility sector.
That concentration is not new, but it has deepened. Of the UK’s 107 treatment clinics, 71, two thirds, are now privately owned, up from 62 just three years earlier in 2021/22. Private providers have grown faster than the sector as a whole, and London, already the country’s single biggest concentration of fertility specialists, has been where a disproportionate share of that private growth has landed.
The scale behind that concentration is considerable. More than 100,000 cycles of fertility treatment, storage or donation took place across UK clinics in 2024/25 alone. The most recent fully broken-down year, 2023, saw around 83,000 treatment cycles, roughly 77,500 IVF and 5,500 donor insemination, and 16,000 storage cycles, split between egg and embryo freezing, across some 63,000 patients. Over 99% of cycles that year had no reported incident, a reassurance on safety that sits alongside the sheer number of decisions, about which clinic, which treatment, which specialist, patients are making at scale every year.
Why has London pulled so far ahead of the rest of the country? Part of it is simply where specialist expertise has historically clustered. London’s long-standing concentration of teaching hospitals, private healthcare groups and research institutions has made it the natural base for fertility medicine in the way it has for many other specialisms. Part of it is commercial: a private fertility clinic needs enough paying patients within reasonable travelling distance to be viable, and no other UK city offers a comparable catchment. And part of it is patient choice rather than necessity.
Patients do not have to use their local NHS-commissioned provider for private treatment the way they might for NHS-funded care, so London’s clinics draw patients well beyond the city’s own boundaries: people travelling in from across the South East and beyond for a specific clinic’s reputation, its published success rate data, or simply a wider choice of appointment times than a single regional clinic can offer.
That concentration brings a genuine advantage for patients willing or able to travel for it: more choice between providers, more specialists working across a larger number of complex cases, and, because the HFEA publishes comparable success rate data for every licensed clinic through its own clinic comparison tool, more ability to compare options directly rather than defaulting to whichever clinic happens to be nearest. It also means more competition on service: counselling support and appointment flexibility are increasingly what clinics compete on, once core success rates across providers sit in a broadly similar range.
The shift towards private ownership is worth sitting with for a moment, too. The number of privately owned treatment clinics nationally rose from 62 to 71 between 2021/22 and 2024/25, so that two-thirds figure is a recent high rather than a long-standing one, and the pattern mirrors what has happened elsewhere in UK private healthcare, where larger groups have acquired standalone clinics to build networks capable of investing in equipment, genetic screening capability and specialist staff that a single independent clinic might struggle to justify on its own. London’s size and patient volume make it the natural place for that kind of investment to land first, which in turn reinforces the city’s advantage over other regions rather than narrowing it over time.
The flip side is obvious. Patients outside London, or those for whom travelling into the city for repeated appointments is not realistic, face a genuinely smaller set of realistic options, something the regional clinic counts above illustrate starkly. Three clinics in Northern Ireland and four in Wales is a very different patient experience from choosing among 36 in a single city, even before NHS funding variation between regions is factored in. It is also why London’s clinics routinely see patients who live well outside the capital: travelling to a city with dozens of providers to choose from, even accounting for the cost and inconvenience of the journey, can still be the more practical option than relying on the one or two clinics realistically reachable from a smaller region.
For the patients who can get to London, though, the practical result of that concentration is straightforward: more established providers, more published outcome data to compare, and more capacity, at least on paper, than almost anywhere else in the country. Choosing afertility clinic in London does not mean narrowing those options down. For most people starting that search, it means the opposite: more providers to choose between than they would find almost anywhere else in the UK.
